Trials / Completed
CompletedNCT00654238
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
Conditions
- Metastatic Differentiated Thyroid Cancer
- Metastatic Poorly Differentiated Thyroid Cancer
- Metastatic Anaplastic Thyroid Cancer
- Metastatic Medullary Thyroid Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sorafenib | 400mg PO BID daily |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2010-12-01
- Completion
- 2011-03-01
- First posted
- 2008-04-07
- Last updated
- 2019-11-18
- Results posted
- 2019-11-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00654238. Inclusion in this directory is not an endorsement.